Zevra Therapeutics, INC Schedule 13G passive stakes

Woodline Partners LP has reported beneficial ownership of 4,785,771 shares, representing 8.1% of Zevra Therapeutics, Inc. common stock.

FMR LLC, along with Abigail P. Johnson, has disclosed a beneficial ownership of 8.3% in Zevra Therapeutics Inc. common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.11% of Zevra Therapeutics Inc. common stock as of June 30, 2026.

FMR LLC, along with Abigail P. Johnson, has reported beneficial ownership of 5.5% of Zevra Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Zevra Therapeutics Inc. following an internal realignment.

Woodline Partners LP has reported a 6.2% beneficial ownership stake in Zevra Therapeutics, Inc., holding 3,476,143 shares of common stock.

Adage Capital Management, L.P. and its principals have filed an amended Schedule 13G, reporting a 3.96% beneficial ownership stake in Zevra Therapeutics, Inc. as of September 30, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.38% in Zevra Therapeutics, Inc. as of December 31, 2024.

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 6.84% in Zevra Therapeutics, Inc., totaling 3,650,000 shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in ZEVRA THERAPEUTICS, INC. as of December 31, 2024.